婴幼儿血管瘤治疗相关机制的研究进展
Research Progress on the Mechanism of Treatment of Infantile Hemangioma
DOI: 10.12677/acm.2024.143877, PDF,   
作者: 孙兴兴：新疆医科大学研究生学院，新疆 乌鲁木齐；丁 媛*：新疆维吾尔自治区人民医院皮肤性病科，新疆皮肤性病临床医学研究中心，新疆皮肤病研究重点实验室，新疆 乌鲁木齐
关键词: 婴幼儿血管瘤；普萘洛尔；皮质类固醇；激光；抗肿瘤药物；Infantile Hemangioma； Propranolol； Corticosteroids； Laser； Antitumor Drug
摘要: 婴幼儿血管瘤(Infantile Hemangioma, IH)是婴幼儿期最常见的以血管内皮细胞异常增殖的良性血管性肿瘤。尽管大多数婴幼儿血管瘤因其自然病程只需要积极观察，但部分仍会导致毁容、影响相应功能、甚至危及生命的风险，需要积极治疗。本文将对近些年婴幼儿血管瘤不同治疗方法及其机制进行综述，以期为婴幼儿血管瘤新的治疗提供理论基础。
Abstract: Infantile hemangioma is the most common benign vascular tumor with abnormal proliferation of vascular endothelial cells in infants. Although most infantile hemangiomas only need active observation because of their natural course, some of them will still lead to disfigurement, affect their corresponding functions and even endanger their lives, and need active treatment. This article will review the different treatment methods and mechanisms of infantile hemangioma in recent years, in order to provide a theoretical basis for the new treatment of infantile hemangioma.
文章引用：孙兴兴, 丁媛. 婴幼儿血管瘤治疗相关机制的研究进展[J]. 临床医学进展, 2024, 14(3): 1544-1549. https://doi.org/10.12677/acm.2024.143877

参考文献

[1] Léauté-Labrèze, C., Prey, S. and Ezzedine, K. (2011) Infantile Haemangioma: Part I. Pathophysiology, Epidemiology, Clinical Features, Life Cycle and Associated Structural Abnormalities. Journal of the European Academy of Dermatology and Venereology, 25, 1245-1253. [Google Scholar] [CrossRef] [PubMed]
[2] Greenberger, S. and Bischoff, J. (2011) Infantile Hemangioma-Mechanism(S) of Drug Action on a Vascular Tumor. Cold Spring Harbor Perspectives in Medicine, 1, a006460. [Google Scholar] [CrossRef] [PubMed]
[3] Satterfield, K.R. and Chambers, C.B. (2019) Current Treatment and Management of Infantile Hemangiomas. Survey of Ophthalmology, 64, 608-618. [Google Scholar] [CrossRef] [PubMed]
[4] Léauté-Labrèze, C., Dumas De La Roque, E., Hubiche, T., et al. (2008) Propranolol for Severe Hemangiomas of Infancy. New England Journal of Medicine, 358, 2649-2651. [Google Scholar] [CrossRef] 
[5] Pandey, V., Tiwari, P., Imran, M., et al. (2021) Adverse Drug Reactions Following Propranolol in Infantile Hemangioma. Indian Pediatrics, 58, 753-755. [Google Scholar] [CrossRef] 
[6] Makkeyah, S.M., Elseedawy, M.E., Abdel-Kader, H.M., et al. (2022) Vascular Endothelial Growth Factor Response with Propranolol Therapy in Patients with Infantile Hemangioma. Pediatric Hematology and Oncology, 39, 215-224. [Google Scholar] [CrossRef] [PubMed]
[7] Rotter, A. and De Oliveira, Z.N.P. (2017) Infantile Hemangioma: Pathogenesis and Mechanisms of Action of Propranolol. Journal Der Deutschen Dermatologischen Gesellschaft, 15, 1185-1190. [Google Scholar] [CrossRef] [PubMed]
[8] Ye, Y., Zhong, H., Dou, L., et al. (2022) Propranolol Inhibits the Angiogenic Capacity of Hemangioma Endothelia via Blocking β-Adrenoceptor in Mast Cell. Pediatric Research, 92, 424-429. [Google Scholar] [CrossRef] [PubMed]
[9] Li, H.H., Lou, Y., Zhang, R.R., et al. (2019) Propranolol Accelerats Hemangioma Stem Cell Transformation into Adipocyte. Annals of Plastic Surgery, 83, e5-e13. [Google Scholar] [CrossRef] 
[10] Zhao, Z.L., Liu, C., Wang, Q.Z., et al. (2022) Engineered Exosomes for Targeted Delivery of MiR-187-3p Suppress the Viability of Hemangioma Stem Cells by Targeting Notch Signaling. Annals of Translational Medicine, 10, Article 621. [Google Scholar] [CrossRef] [PubMed]
[11] Liu, C., Zhao, Z., Ji, Z., et al. (2019) MiR-187-3p Enhances Propranolol Sensitivity of Hemangioma Stem Cells. Cell Structure and Function, 44, 41-50. [Google Scholar] [CrossRef] [PubMed]
[12] Huang, J., Jiang, D., Zhao, S., et al. (2019) Propranolol Suppresses Infantile Hemangioma Cell Proliferation and Promotes Apoptosis by Upregulating MiR-125b Expression. Anti-Cancer Drugs, 30, 501-507. [Google Scholar] [CrossRef] 
[13] Wu, Z.B., Shi, S.L., et al. (2021) Propranolol Inhibits Infantile Hemangioma by Regulating the MiR-424/Vascular Endothelial Growth Factor-A (VEGFA) Axis. Translational Pediatrics, 10, 1867-1876. [Google Scholar] [CrossRef] [PubMed]
[14] Li, D., Li, P., Guo, Z., et al. (2017) Downregulation of MiR-382 by Propranolol Inhibits the Progression of Infantile Hemangioma via the PTEN-Mediated AKT/MTOR Pathway. International Journal of Molecular Medicine, 39, 757-763. [Google Scholar] [CrossRef] [PubMed]
[15] Hasan, Q., Tan, S.T., Gush, J., et al. (2000) Steroid Therapy of a Proliferating Hemangioma: Histochemical and Molecular Changes. Pediatrics, 105, 117-120. [Google Scholar] [CrossRef] [PubMed]
[16] Greenberger, S., Boscolo, E., Adini, I., et al. (2010) Corticosteroid Suppression of VEGF-A in Infantile Hemangioma-Derived Stem Cells. New England Journal of Medicine, 362, 1005-1013. [Google Scholar] [CrossRef] 
[17] Zhang, L., Wu, H.W., Yuan, W., et al. (2017) Estrogen-Mediated Hemangioma-Derived Stem Cells through Estrogen Receptor-α for Infantile Hemangioma. Cancer Management and Research, 9, 279-286. [Google Scholar] [CrossRef] 
[18] George, M.E., Sharma, V., Jacobson, J., et al. (2004) Adverse Effects of Systemic Glucocorticosteroid Therapy in Infants with Hemangiomas. Archives of Dermatology, 140, 963-969. [Google Scholar] [CrossRef] [PubMed]
[19] Tu, J.B., Li, Q.Y., Jiang, F., et al. (2014) Pingyangmycin Stimulates Apoptosis in Human Hemangioma-Derived Endothelial Cells through Activation of the P53 Pathway. Molecular Medicine Reports, 10, 301-305. [Google Scholar] [CrossRef] [PubMed]
[20] Sgonc, R., Fuerhapter, C., Boeck, G., et al. (1998) Induction of Apoptosis in Human Dermal Microvascular Endothelial Cells and Infantile Hemangiomas by Interferon-α. International Archives of Allergy and Immunology, 117, 209-214.
[21] 范琴, 王树坚, 李娜, 等. 婴儿血管瘤的研究进展[J]. 当代医学, 2022, 28(17): 187-190.
[22] Cao, Y., Wang, F., Jia, Q., et al. (2014) One Possible Mechanism of Pulsed Dye Laser Treatment on Infantile Hemangioma: Induction of Endothelial Apoptosis and Serum Vascular Endothelial Growth Factor (VEGF) Level Changes. Journal of Lasers in Medical Sciences, 5, 75-81.
[23] Rocco, R., Alegre, N., Pozner, R., et al. (2018) Selective Hemangioma Cell Dysfunction and Apoptosis Triggered by in Vitro Treatment with Imiquimod. Toxicology Letters, 288, 82-88. [Google Scholar] [CrossRef] [PubMed]
[24] Wang, Y., Chen, J., Tang, W., et al. (2017) Rapamycin Inhibits the Proliferation of Endothelial Cells in Hemangioma by Blocking the MTOR-FABP4 Pathway. Biomedicine & Pharmacotherapy, 85, 272-279. [Google Scholar] [CrossRef] [PubMed]
[25] 高晓芸, 温俊平, 杨宇. PI3K/AKT/MTOR/4EBP1信号通路在体外培养血管瘤血管内皮细胞中的表达[J]. 中外医学研究, 2019, 17(3): 1-4.
[26] Ran, Y., Chen, S., Dai, Y., et al. (2015) Successful Treatment of Oral Itraconazole for Infantile Hemangiomas: A Case Series. Journal of Dermatology, 42, 202-206. [Google Scholar] [CrossRef] [PubMed]
[27] Chen, S., Zhuang, K., Sun, K., et al. (2019) Itraconazole Induces Regression of Infantile Hemangioma via Downregulation of the Platelet-Derived Growth Factor-D/PI3K/Akt/MTOR Pathway. Journal of Investigative Dermatology, 139, 1574-1582. [Google Scholar] [CrossRef] [PubMed]
[28] Xie, C., Xu, X., Wang, X., et al. (2018) Cyclooxygenase-2 Induces Angiogenesis in Pancreatic Cancer Mediated by Prostaglandin E2. Oncology Letters, 16, 940-948. [Google Scholar] [CrossRef] [PubMed]
[29] Wang, Y., Kong, L., Sun, B., et al. (2022) Celecoxib Induces Adipogenic Differentiation of Hemangioma-Derived Mesenchymal Stem Cells through the PPAR-γ Pathway in Vitro and in Vivo. Experimental and Therapeutic Medicine, 23, Article No. 375. [Google Scholar] [CrossRef] [PubMed]

为你推荐